The ALITHIOS open-label extension study showed continuous treatment with Kesimpta ® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS) patients was associated with reduced risk of ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use (EMA’s CHMP) recommended 13 new medicines for approval when it met in January. The committee recommended conditional ...
Novartis is highlighting six products as key engines for the company’s mid-term growth. Among them, new multiple sclerosis drug Kesimpta and relatively slow-ramping breast cancer med Kisqali earned a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results